These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 24729689)

  • 1. Treatment selection and experience in multiple sclerosis: survey of neurologists.
    Hanson KA; Agashivala N; Wyrwich KW; Raimundo K; Kim E; Brandes DW
    Patient Prefer Adherence; 2014; 8():415-22. PubMed ID: 24729689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and future trends in multiple sclerosis management: Near East perspective.
    Hatem A; El Ayoubi NK; Habahbeh M; Ghanim Z; Al-Naqshbandi M; Raki A; Joudi H; Sahraian MA
    Mult Scler Relat Disord; 2023 Aug; 76():104800. PubMed ID: 37307691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
    J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.
    Agashivala N; Wu N; Abouzaid S; Wu Y; Kim E; Boulanger L; Brandes DW
    BMC Neurol; 2013 Oct; 13():138. PubMed ID: 24093542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis.
    Eagle T; Stuart F; Chua AS; LaRussa A; Leclaire K; Cook SL; Chitnis T; Weiner HL; Glanz BI; Healy BC
    Mult Scler Relat Disord; 2017 Nov; 18():196-201. PubMed ID: 29141809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How the COVID-19 Pandemic has changed multiple sclerosis clinical practice: Results of a nationwide provider survey.
    Morrison EH; Michtich K; Hersh CM
    Mult Scler Relat Disord; 2021 Jun; 51():102913. PubMed ID: 33839482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool.
    Col NF; Solomon AJ; Alvarez E; Pbert L; Ionete C; BerriosMorales I; Chester J; Kutz C; Iwuchukwu C; Livingston T; Springmann V; Col HV; Ngo LH
    Mult Scler Relat Disord; 2023 Dec; 80():105092. PubMed ID: 37931489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
    Calkwood J; Cree B; Crayton H; Kantor D; Steingo B; Barbato L; Hashmonay R; Agashivala N; McCague K; Tenenbaum N; Edwards K
    BMC Neurol; 2014 Nov; 14():220. PubMed ID: 25424122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
    Neuberger EE; Abbass IM; Jones E; Engmann NJ
    Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in multiple sclerosis care: Results from an international mixed-methods study.
    Péloquin S; Schmierer K; Leist TP; Oh J; Murray S; Lazure P
    Mult Scler Relat Disord; 2021 May; 50():102854. PubMed ID: 33690086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of diagnosis and treatment practices of Brazilian neurologists among patients with multiple sclerosis.
    Marin CE; Callegaro D; Lana-Peixoto MA; Fernández O; Gomes Neto AP; Vasconcelos CCF; d'Almeida JAC; Gonçalves MVM; Mendes MF; Parolin MKF; Nascimento O; Gama PDD; Dias-Carneiro RPC; Dias RM; Damasceno A; Becker J
    Arq Neuropsiquiatr; 2021 Jul; 79(7):598-606. PubMed ID: 34468497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
    Johnston J; So TY
    Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study.
    Zecca C; Disanto G; Mühl S; Gobbi C
    BMC Neurol; 2017 Sep; 17(1):171. PubMed ID: 28870152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to Disease-Modifying Therapies for Multiple Sclerosis.
    Higuera L; Carlin CS; Anderson S
    J Manag Care Spec Pharm; 2016 Dec; 22(12):1394-1401. PubMed ID: 27882830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
    Chen J; Taylor BV; Blizzard L; Simpson S; Palmer AJ; van der Mei IAF
    J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1200-1207. PubMed ID: 29921609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
    Hartung DM; Bourdette DN; Ahmed SM; Whitham RH
    Neurology; 2015 May; 84(21):2185-92. PubMed ID: 25911108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple sclerosis disease-modifying therapy prescribing patterns in Ontario.
    Marriott JJ; Mamdani M; Saposnik G; Gomes T; Manno M; O'Connor PW
    Can J Neurol Sci; 2013 Jan; 40(1):67-72. PubMed ID: 23250130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of COVID-19 on prescribing patterns and treatment selection of disease modifying therapies in multiple sclerosis.
    Zaheer R; Amin R; Riddick L; Roy S; Wolff S; Nathanson A; Newsome S
    Mult Scler Relat Disord; 2023 Mar; 71():104575. PubMed ID: 36857853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.